Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer

Xiao Hong Bao, Munenori Takaoka, Hui Fang Hao, Takuya Fukazawa, Tomoki Yamatsuji, Kazufumi Sakurama, Nagio Takigawa, Motowo Nakajima, Toshiyoshi Fujiwara, Yoshio Naomoto

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Heat shock protein 90 (HSP90), a molecular chaperone, has provoked great interest as a promising molecular target for cancer treatment, due to its involvement in regulating the conformation, stability and functions of key oncogenic proteins. At present, a variety of chemical compounds targeting HSP90 have been developed and have shown convincing anti-neoplastic activity in various preclinical tumor models. The aim of our study was to evaluate the antitumor effects of a novel HSP90 inhibitor, NVP-AUY922, in esophageal squamous cancer cells (ESCC). Four ESCC cell lines (TE-1, TE-4, TE-8, TE-10) were examined. NVP-AUY922 potently inhibited the proliferation of ESCC, particularly in PTEN-null TE-4 cells with a 2-3 times lower IC50 than the other three cell lines. Western blot analysis showed that PTEN-null TE-4 cells exhibited higher AKT and ERK activity, which contribute to cell proliferation and survival. NVP-AUY922 significantly suppressed the activity of AKT and ERK in TE-4 but not in PTEN-proficient TE-10 cells. Genetic modification experiments demonstrated that the sensitivity to NVP-AUY922 was decreased by exogenous transduction of PTEN in TE-4 and increased by silencing PTEN expression in intact PTEN-expressing TE-10, suggesting that the expression of PTEN may be associated with cell sensitivity in HSP90 inhibition. Furthermore, the enhanced activity of AKT in PTEN-silenced TE-10 was more easily suppressed by NVP-AUY922. Collectively, NVP-AUY922 exhibits a strong antiproliferative effect, revealing its potential as a novel therapeutic alternative to current ESCC treatment. The effect may be improved further by impeding PTEN expression.

Original languageEnglish
Pages (from-to)45-50
Number of pages6
JournalOncology Reports
Volume29
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

HSP90 Heat-Shock Proteins
Esophageal Neoplasms
Epithelial Cells
Cell Line
Molecular Chaperones
Inhibitory Concentration 50
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
Neoplasms
Cell Survival
Western Blotting
Cell Proliferation
Proteins

Keywords

  • Esophageal cancer
  • Heat shock protein 90
  • NVP-AUY922
  • PTEN

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bao, X. H., Takaoka, M., Hao, H. F., Fukazawa, T., Yamatsuji, T., Sakurama, K., ... Naomoto, Y. (2013). Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer. Oncology Reports, 29(1), 45-50. https://doi.org/10.3892/or.2012.2074

Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer. / Bao, Xiao Hong; Takaoka, Munenori; Hao, Hui Fang; Fukazawa, Takuya; Yamatsuji, Tomoki; Sakurama, Kazufumi; Takigawa, Nagio; Nakajima, Motowo; Fujiwara, Toshiyoshi; Naomoto, Yoshio.

In: Oncology Reports, Vol. 29, No. 1, 01.2013, p. 45-50.

Research output: Contribution to journalArticle

Bao, XH, Takaoka, M, Hao, HF, Fukazawa, T, Yamatsuji, T, Sakurama, K, Takigawa, N, Nakajima, M, Fujiwara, T & Naomoto, Y 2013, 'Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer', Oncology Reports, vol. 29, no. 1, pp. 45-50. https://doi.org/10.3892/or.2012.2074
Bao, Xiao Hong ; Takaoka, Munenori ; Hao, Hui Fang ; Fukazawa, Takuya ; Yamatsuji, Tomoki ; Sakurama, Kazufumi ; Takigawa, Nagio ; Nakajima, Motowo ; Fujiwara, Toshiyoshi ; Naomoto, Yoshio. / Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer. In: Oncology Reports. 2013 ; Vol. 29, No. 1. pp. 45-50.
@article{5e04b4e81c39463b8865031a3b4a10a0,
title = "Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer",
abstract = "Heat shock protein 90 (HSP90), a molecular chaperone, has provoked great interest as a promising molecular target for cancer treatment, due to its involvement in regulating the conformation, stability and functions of key oncogenic proteins. At present, a variety of chemical compounds targeting HSP90 have been developed and have shown convincing anti-neoplastic activity in various preclinical tumor models. The aim of our study was to evaluate the antitumor effects of a novel HSP90 inhibitor, NVP-AUY922, in esophageal squamous cancer cells (ESCC). Four ESCC cell lines (TE-1, TE-4, TE-8, TE-10) were examined. NVP-AUY922 potently inhibited the proliferation of ESCC, particularly in PTEN-null TE-4 cells with a 2-3 times lower IC50 than the other three cell lines. Western blot analysis showed that PTEN-null TE-4 cells exhibited higher AKT and ERK activity, which contribute to cell proliferation and survival. NVP-AUY922 significantly suppressed the activity of AKT and ERK in TE-4 but not in PTEN-proficient TE-10 cells. Genetic modification experiments demonstrated that the sensitivity to NVP-AUY922 was decreased by exogenous transduction of PTEN in TE-4 and increased by silencing PTEN expression in intact PTEN-expressing TE-10, suggesting that the expression of PTEN may be associated with cell sensitivity in HSP90 inhibition. Furthermore, the enhanced activity of AKT in PTEN-silenced TE-10 was more easily suppressed by NVP-AUY922. Collectively, NVP-AUY922 exhibits a strong antiproliferative effect, revealing its potential as a novel therapeutic alternative to current ESCC treatment. The effect may be improved further by impeding PTEN expression.",
keywords = "Esophageal cancer, Heat shock protein 90, NVP-AUY922, PTEN",
author = "Bao, {Xiao Hong} and Munenori Takaoka and Hao, {Hui Fang} and Takuya Fukazawa and Tomoki Yamatsuji and Kazufumi Sakurama and Nagio Takigawa and Motowo Nakajima and Toshiyoshi Fujiwara and Yoshio Naomoto",
year = "2013",
month = "1",
doi = "10.3892/or.2012.2074",
language = "English",
volume = "29",
pages = "45--50",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer

AU - Bao, Xiao Hong

AU - Takaoka, Munenori

AU - Hao, Hui Fang

AU - Fukazawa, Takuya

AU - Yamatsuji, Tomoki

AU - Sakurama, Kazufumi

AU - Takigawa, Nagio

AU - Nakajima, Motowo

AU - Fujiwara, Toshiyoshi

AU - Naomoto, Yoshio

PY - 2013/1

Y1 - 2013/1

N2 - Heat shock protein 90 (HSP90), a molecular chaperone, has provoked great interest as a promising molecular target for cancer treatment, due to its involvement in regulating the conformation, stability and functions of key oncogenic proteins. At present, a variety of chemical compounds targeting HSP90 have been developed and have shown convincing anti-neoplastic activity in various preclinical tumor models. The aim of our study was to evaluate the antitumor effects of a novel HSP90 inhibitor, NVP-AUY922, in esophageal squamous cancer cells (ESCC). Four ESCC cell lines (TE-1, TE-4, TE-8, TE-10) were examined. NVP-AUY922 potently inhibited the proliferation of ESCC, particularly in PTEN-null TE-4 cells with a 2-3 times lower IC50 than the other three cell lines. Western blot analysis showed that PTEN-null TE-4 cells exhibited higher AKT and ERK activity, which contribute to cell proliferation and survival. NVP-AUY922 significantly suppressed the activity of AKT and ERK in TE-4 but not in PTEN-proficient TE-10 cells. Genetic modification experiments demonstrated that the sensitivity to NVP-AUY922 was decreased by exogenous transduction of PTEN in TE-4 and increased by silencing PTEN expression in intact PTEN-expressing TE-10, suggesting that the expression of PTEN may be associated with cell sensitivity in HSP90 inhibition. Furthermore, the enhanced activity of AKT in PTEN-silenced TE-10 was more easily suppressed by NVP-AUY922. Collectively, NVP-AUY922 exhibits a strong antiproliferative effect, revealing its potential as a novel therapeutic alternative to current ESCC treatment. The effect may be improved further by impeding PTEN expression.

AB - Heat shock protein 90 (HSP90), a molecular chaperone, has provoked great interest as a promising molecular target for cancer treatment, due to its involvement in regulating the conformation, stability and functions of key oncogenic proteins. At present, a variety of chemical compounds targeting HSP90 have been developed and have shown convincing anti-neoplastic activity in various preclinical tumor models. The aim of our study was to evaluate the antitumor effects of a novel HSP90 inhibitor, NVP-AUY922, in esophageal squamous cancer cells (ESCC). Four ESCC cell lines (TE-1, TE-4, TE-8, TE-10) were examined. NVP-AUY922 potently inhibited the proliferation of ESCC, particularly in PTEN-null TE-4 cells with a 2-3 times lower IC50 than the other three cell lines. Western blot analysis showed that PTEN-null TE-4 cells exhibited higher AKT and ERK activity, which contribute to cell proliferation and survival. NVP-AUY922 significantly suppressed the activity of AKT and ERK in TE-4 but not in PTEN-proficient TE-10 cells. Genetic modification experiments demonstrated that the sensitivity to NVP-AUY922 was decreased by exogenous transduction of PTEN in TE-4 and increased by silencing PTEN expression in intact PTEN-expressing TE-10, suggesting that the expression of PTEN may be associated with cell sensitivity in HSP90 inhibition. Furthermore, the enhanced activity of AKT in PTEN-silenced TE-10 was more easily suppressed by NVP-AUY922. Collectively, NVP-AUY922 exhibits a strong antiproliferative effect, revealing its potential as a novel therapeutic alternative to current ESCC treatment. The effect may be improved further by impeding PTEN expression.

KW - Esophageal cancer

KW - Heat shock protein 90

KW - NVP-AUY922

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=84872856102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872856102&partnerID=8YFLogxK

U2 - 10.3892/or.2012.2074

DO - 10.3892/or.2012.2074

M3 - Article

VL - 29

SP - 45

EP - 50

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -